Neural progenitor cell lines inhibit rat tumor growth in vivo
Karin Staflin1, Gabriella Honeth, Suzanne Kalliomäki
1Department of Cell and Molecular Biology, Section for Tumor Biology, Lund University BMC: I 12, S-221 84 Lund, Sweden. karin.staflin@tumor.lu.se
Abstract:
Current therapies for gliomas often fail to address their infiltrative nature. Conventional treatments leave behind small clusters of neoplastic cells, resulting in eventual tumor recurrence. In the present study, we have evaluated the antitumor activity of neural progenitor cells against gliomas when stereotactically injected into nucleus Caudatus of Fisher rats. We show that the rat neural progenitor cell lines HiB5 and ST14A, from embryonic hippocampus and striatum primordium, respectively, are able to prolong animal survival and, in 25% of the cases, completely inhibit the outgrowth of N29 glioma compared with control animals. Delayed tumor outgrowth was also seen when HiB5 cells were inoculated at the site of tumor growth 1 week after tumor inoculation or when a mixture of tumor cells and HiB5 cells were injected s.c. into Fisher rats. HiB5 cells were additionally coinoculated together with two alternative rat gliomas, N32 and N25. N32 was growth inhibited, but rats inoculated with N25 cells did not show a prolonged survival. To evaluate the possibility of the involvement of the immune system in the tumor outgrowth inhibition, we show that HiB5 cells do not evoke an immune response when injected into Fisher rats. Furthermore, the rat neural progenitor cells produce all transforming growth factor beta isotypes, which could explain the observed immunosuppressive nature of these cells. Hence, some neural progenitor cells have the ability to inhibit tumor outgrowth when implanted into rats. These results indicate the usefulness of neural stem cells as therapeutically effective cells for the treatment of intracranial tumors.
Insights
Neural progenitor cells show promise in treating gliomas by inhibiting tumor growth and prolonging survival in rats. These cells may offer a new therapeutic strategy for intracranial tumors.
Area of Science:
- Neuroscience
- Oncology
- Stem Cell Biology
Background:
- Gliomas are challenging to treat due to their infiltrative nature, leading to tumor recurrence after conventional therapies.
- Current treatments often fail to eliminate all neoplastic cells, necessitating novel therapeutic approaches.
Purpose of the Study:
- To evaluate the antitumor activity of neural progenitor cells against gliomas in a rat model.
- To investigate the potential of neural progenitor cells as a therapeutic strategy for intracranial tumors.
Main Methods:
- Stereotactic injection of rat neural progenitor cell lines (HiB5 and ST14A) into the nucleus Caudatus of Fisher rats with N29 glioma.
- Assessment of animal survival rates and tumor outgrowth inhibition.
- Evaluation of neural progenitor cell inoculation at tumor sites and in combination with different glioma cell lines (N32, N25).
- Investigation of the immune response to neural progenitor cell implantation and the role of transforming growth factor beta (TGF-β).
Main Results:
- Neural progenitor cell lines HiB5 and ST14A significantly prolonged animal survival and completely inhibited N29 glioma outgrowth in 25% of cases.
- Delayed tumor outgrowth was observed when HiB5 cells were administered at the tumor site or mixed with tumor cells.
- HiB5 cells inhibited N32 glioma growth but did not prolong survival with N25 glioma.
- HiB5 cells did not elicit an immune response and produced TGF-β, suggesting an immunosuppressive mechanism.
Conclusions:
- Certain neural progenitor cells demonstrate significant antitumor activity against gliomas in rats.
- Neural progenitor cells, potentially through immunosuppression via TGF-β, offer a promising therapeutic avenue for intracranial tumors.
- These findings highlight the potential of neural stem cells in treating brain tumors.
